Nanogen erhält neues US Patent! Kurschancen stehen groß! - 500 Beiträge pro Seite
eröffnet am 04.12.03 10:53:05 von
neuester Beitrag 08.12.03 17:10:34 von
neuester Beitrag 08.12.03 17:10:34 von
Beiträge: 56
ID: 801.555
ID: 801.555
Aufrufe heute: 1
Gesamt: 2.163
Gesamt: 2.163
Aktive User: 0
ISIN: US6300751095 · WKN: 911841
Werte aus der Branche Nanotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5060 | +6,30 | |
| 1,9820 | +3,88 | |
| 1,0500 | +2,94 | |
| 1,3378 | +1,36 | |
| 43,70 | +0,58 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7495 | -0,66 | |
| 29,60 | -1,00 | |
| 71,00 | -1,39 | |
| 2,6700 | -1,66 | |
| 1,6700 | -19,71 |
Feedback
SmartMoney.com
A Tiny Triumph
Wednesday December 3, 6:10 pm ET
By Lawrence Carrel
Nanogen, Inc. (NASDAQ:NGEN - News)
Share price as of Tuesday`s close: $3.79
Share price now: $5.74
Change: 51.5%
Volume: 29.3 million shares, daily average 152,800 shares
Last time this high: Jan. 7, 2002
52-week high: $4.98
52-week low: $1.00
Forward P/E before announcement: n/a
Forward P/E after announcement: n/a
WOULD YOU KNOW a "top-down electric field process" from "the bottom-up DNA self-assembly?"
If so, you`re unusually qualified to judge the value of the ninth patent obtained this year by suitably tiny nanotech pioneer Nanogen (NASDAQ:NGEN - News).
The rest of us will just have to live with the company`s assessment that it`s "key" and the market`s verdict that proprietary insights into "an electric field assisted manufacturing platform and programmable self-assembling nanostructures" were worthy of a 51% share-price surge to a two-year high of $5.74.
Nanotechnology, a blend of chemistry and engineering, creates tiny devices or systems that operate on atomic and molecular scales. A nanometer is a billionth of a meter. By comparison, a single human cell is between 5,000 and 10,000 nanometers long.
One day, nanotech might put a supercomputer on the head of the pin. For the moment, however, it`s hard pressed to turn a profit.
Still, the microscopic discipline is enjoying lots of buzz as The Next Big Thing. On Wednesday, President Bush signed the 21st Century Nanotechnology Research and Development Act, authorizing $3.7 billion in nanotech research funding over the next four years.
Also Wednesday, Merrill Lynch held a conference call on nanotechnology. Analyst John Roy tried to convince investors that "nanotechnology could become the next growth innovation." Roy foresees uses in the fields of enhanced materials, hard-disk drives, optical networking, memory chips, medical drugs and genomic testing. And while Merrill tech strategist Steve Milunovich said during the same call that "nanotech will be over-hyped," he added that "where there`s smoke there`s fire. Nanotech is real and the intellectual-property barriers are much higher than for the Internet."
Such helpful speculation has helped Nanogen shares gain 463% since its March lows, though they still fetch less than one-sixteenth of the all-time high set in March 2000.
The latest patent, the San Diego company`s 56th overall, is the first in a series of pending applications related to the same advance. "If you think nanotechnology will be valuable in the future, this patent could be very valuable," says Tom Heinzen, vice president of Emergent Financial Group, a Minneapolis brokerage.
The company seems to agree. "The patent is important because it pertains to fundamental methods of fabricating components," says Michael Heller, a professor of bioengineering and electrical engineering at the University of California, San Diego. He co-founded Nanogen and worked on the new technology. "It`s a microchip that produces electrical fields that can control the assembly of nanocomponents. It can manipulate the nanoparticles using the electric field device," he explains
According to Heller, nanocomponents can incorporate DNA sequences giving them specific binding affinity, in effect instructions for a process of self-assembly. He says the electric fields help guide and control the self-assembly process, and allow it to be replicated on a wide scale.
"The process will help create nanostructures that can be used to create things such as features on computer chips like transistors and memory elements," says Heller. "There is a lot of evolutionary progress in the field. There are a lot of pragmatic applications, but what you haven`t seen is anything revolutionary. We haven`t seen the paradigm change yet."
Nanoparticle materials are currently being used in some not-so-sexy applications, such as grinding and polishing agents.
What little revenue Nanogen currently has comes from the development of molecular diagnostic products. It currently sells two: the NanoChip Molecular Biology Workstation, a platform for detecting genetic mutations with forensic and biowarfare applications, and the disposable cartridges used by that platform. The products have been on the market less than two years, and the 10-year-old company remains unprofitable.
For the third quarter, it posted a net loss of $7.1 million, or 33 cents a share, a 14% improvement from the year-earlier period. Revenues jumped 12% year-over-year to $1.7 million, based on 10 sales or rentals of the workstation.
Heinzen is a fan of the company`s management. Howard Birndorf, Nanogen`s chairman and chief executive, founded six other companies, including Idec Pharmaceuticals, Ligand Pharmaceuticals (NASDAQ:LGND - News) and Gen-Probe (NASDAQ:GPRO - News). "He`s got a track record of success," says Heinzen. "He knows the bio industries and he`s the first reason we looked at it."
Others are also getting on board. The $32.6 million in cash Nanogen had at the end of the quarter represented a $4.1 million increase from the prior period, thanks to a private-equity placement that grossed $7 million in fresh capital. As part of the deal, investors received five-year warrants to purchase common stock at an exercise price of $4.75 a share, 12-month warrants at $4.75 a share and six-month warrants at $4.14 a share. If the stock stays at its current price, and investors exercise all their options, the company could receive an additional $9 million in cash.
At the end of the quarter, Nanogen forecast 2003 product revenue of less than $4 million and research revenue of $4 million. The loss for the year could approach $29 million, with cash holdings pegged at $28 million to $30 million. The company expects revenue to increase by 50% in 2004.
Quote:
"They know how to do things on a small scale and they are broadening their knowledge to get patents in other aspects in nanotechnology," says Heinzen of Emergent Financial Group. "We like the current workstation. We think it`s better, faster and will get cheaper. We think the platform will succeed. These patents are the cherry on the sundae. From the way I read it, it doesn`t deal with their day-to-day operations. But there are quite a few people out there that are looking for companies that have knowledge and patents in nanotechnology." (Heinzen owns shares of Nanogen; Emergent Financial Group doesn`t have an investment-banking relationship with the company.)
More SmartMoney.com
A Tiny Triumph
Wednesday December 3, 6:10 pm ET
By Lawrence Carrel
Nanogen, Inc. (NASDAQ:NGEN - News)
Share price as of Tuesday`s close: $3.79
Share price now: $5.74
Change: 51.5%
Volume: 29.3 million shares, daily average 152,800 shares
Last time this high: Jan. 7, 2002
52-week high: $4.98
52-week low: $1.00
Forward P/E before announcement: n/a
Forward P/E after announcement: n/a
WOULD YOU KNOW a "top-down electric field process" from "the bottom-up DNA self-assembly?"
If so, you`re unusually qualified to judge the value of the ninth patent obtained this year by suitably tiny nanotech pioneer Nanogen (NASDAQ:NGEN - News).
The rest of us will just have to live with the company`s assessment that it`s "key" and the market`s verdict that proprietary insights into "an electric field assisted manufacturing platform and programmable self-assembling nanostructures" were worthy of a 51% share-price surge to a two-year high of $5.74.
Nanotechnology, a blend of chemistry and engineering, creates tiny devices or systems that operate on atomic and molecular scales. A nanometer is a billionth of a meter. By comparison, a single human cell is between 5,000 and 10,000 nanometers long.
One day, nanotech might put a supercomputer on the head of the pin. For the moment, however, it`s hard pressed to turn a profit.
Still, the microscopic discipline is enjoying lots of buzz as The Next Big Thing. On Wednesday, President Bush signed the 21st Century Nanotechnology Research and Development Act, authorizing $3.7 billion in nanotech research funding over the next four years.
Also Wednesday, Merrill Lynch held a conference call on nanotechnology. Analyst John Roy tried to convince investors that "nanotechnology could become the next growth innovation." Roy foresees uses in the fields of enhanced materials, hard-disk drives, optical networking, memory chips, medical drugs and genomic testing. And while Merrill tech strategist Steve Milunovich said during the same call that "nanotech will be over-hyped," he added that "where there`s smoke there`s fire. Nanotech is real and the intellectual-property barriers are much higher than for the Internet."
Such helpful speculation has helped Nanogen shares gain 463% since its March lows, though they still fetch less than one-sixteenth of the all-time high set in March 2000.
The latest patent, the San Diego company`s 56th overall, is the first in a series of pending applications related to the same advance. "If you think nanotechnology will be valuable in the future, this patent could be very valuable," says Tom Heinzen, vice president of Emergent Financial Group, a Minneapolis brokerage.
The company seems to agree. "The patent is important because it pertains to fundamental methods of fabricating components," says Michael Heller, a professor of bioengineering and electrical engineering at the University of California, San Diego. He co-founded Nanogen and worked on the new technology. "It`s a microchip that produces electrical fields that can control the assembly of nanocomponents. It can manipulate the nanoparticles using the electric field device," he explains
According to Heller, nanocomponents can incorporate DNA sequences giving them specific binding affinity, in effect instructions for a process of self-assembly. He says the electric fields help guide and control the self-assembly process, and allow it to be replicated on a wide scale.
"The process will help create nanostructures that can be used to create things such as features on computer chips like transistors and memory elements," says Heller. "There is a lot of evolutionary progress in the field. There are a lot of pragmatic applications, but what you haven`t seen is anything revolutionary. We haven`t seen the paradigm change yet."
Nanoparticle materials are currently being used in some not-so-sexy applications, such as grinding and polishing agents.
What little revenue Nanogen currently has comes from the development of molecular diagnostic products. It currently sells two: the NanoChip Molecular Biology Workstation, a platform for detecting genetic mutations with forensic and biowarfare applications, and the disposable cartridges used by that platform. The products have been on the market less than two years, and the 10-year-old company remains unprofitable.
For the third quarter, it posted a net loss of $7.1 million, or 33 cents a share, a 14% improvement from the year-earlier period. Revenues jumped 12% year-over-year to $1.7 million, based on 10 sales or rentals of the workstation.
Heinzen is a fan of the company`s management. Howard Birndorf, Nanogen`s chairman and chief executive, founded six other companies, including Idec Pharmaceuticals, Ligand Pharmaceuticals (NASDAQ:LGND - News) and Gen-Probe (NASDAQ:GPRO - News). "He`s got a track record of success," says Heinzen. "He knows the bio industries and he`s the first reason we looked at it."
Others are also getting on board. The $32.6 million in cash Nanogen had at the end of the quarter represented a $4.1 million increase from the prior period, thanks to a private-equity placement that grossed $7 million in fresh capital. As part of the deal, investors received five-year warrants to purchase common stock at an exercise price of $4.75 a share, 12-month warrants at $4.75 a share and six-month warrants at $4.14 a share. If the stock stays at its current price, and investors exercise all their options, the company could receive an additional $9 million in cash.
At the end of the quarter, Nanogen forecast 2003 product revenue of less than $4 million and research revenue of $4 million. The loss for the year could approach $29 million, with cash holdings pegged at $28 million to $30 million. The company expects revenue to increase by 50% in 2004.
Quote:
"They know how to do things on a small scale and they are broadening their knowledge to get patents in other aspects in nanotechnology," says Heinzen of Emergent Financial Group. "We like the current workstation. We think it`s better, faster and will get cheaper. We think the platform will succeed. These patents are the cherry on the sundae. From the way I read it, it doesn`t deal with their day-to-day operations. But there are quite a few people out there that are looking for companies that have knowledge and patents in nanotechnology." (Heinzen owns shares of Nanogen; Emergent Financial Group doesn`t have an investment-banking relationship with the company.)
More SmartMoney.com
Gestern wurde 1mal der ganze Free Float umgewälzt!
Der größte Aktienumsatz seit es Nanogen an der Börse gibt!
Der größte Aktienumsatz seit es Nanogen an der Börse gibt!
WOULD YOU KNOW a "top-down electric field process" from "the bottom-up DNA self-assembly?"
If so, you`re unusually qualified to judge the value of the ninth patent obtained this year by suitably tiny nanotech pioneer Nanogen (NASDAQ:NGEN - News).
The rest of us will just have to live with the company`s assessment that it`s "key" and the market`s verdict that proprietary insights into "an electric field assisted manufacturing platform and programmable self-assembling nanostructures" were worthy of a 51% share-price surge to a two-year high of $5.74.
Nanotechnology, a blend of chemistry and engineering, creates tiny devices or systems that operate on atomic and molecular scales. A nanometer is a billionth of a meter. By comparison, a single human cell is between 5,000 and 10,000 nanometers long.
One day, nanotech might put a supercomputer on the head of the pin. For the moment, however, it`s hard pressed to turn a profit.
Still, the microscopic discipline is enjoying lots of buzz as The Next Big Thing. On Wednesday, President Bush signed the 21st Century Nanotechnology Research and Development Act, authorizing $3.7 billion in nanotech research funding over the next four years.
Also Wednesday, Merrill Lynch held a conference call on nanotechnology. Analyst John Roy tried to convince investors that "nanotechnology could become the next growth innovation." Roy foresees uses in the fields of enhanced materials, hard-disk drives, optical networking, memory chips, medical drugs and genomic testing. And while Merrill tech strategist Steve Milunovich said during the same call that "nanotech will be over-hyped," he added that "where there`s smoke there`s fire. Nanotech is real and the intellectual-property barriers are much higher than for the Internet."
Such helpful speculation has helped Nanogen shares gain 463% since its March lows, though they still fetch less than one-sixteenth of the all-time high set in March 2000.
The latest patent, the San Diego company`s 56th overall, is the first in a series of pending applications related to the same advance. "If you think nanotechnology will be valuable in the future, this patent could be very valuable," says Tom Heinzen, vice president of Emergent Financial Group, a Minneapolis brokerage.
The company seems to agree. "The patent is important because it pertains to fundamental methods of fabricating components," says Michael Heller, a professor of bioengineering and electrical engineering at the University of California, San Diego. He co-founded Nanogen and worked on the new technology. "It`s a microchip that produces electrical fields that can control the assembly of nanocomponents. It can manipulate the nanoparticles using the electric field device," he explains
According to Heller, nanocomponents can incorporate DNA sequences giving them specific binding affinity, in effect instructions for a process of self-assembly. He says the electric fields help guide and control the self-assembly process, and allow it to be replicated on a wide scale.
"The process will help create nanostructures that can be used to create things such as features on computer chips like transistors and memory elements," says Heller. "There is a lot of evolutionary progress in the field. There are a lot of pragmatic applications, but what you haven`t seen is anything revolutionary. We haven`t seen the paradigm change yet."
Nanoparticle materials are currently being used in some not-so-sexy applications, such as grinding and polishing agents.
What little revenue Nanogen currently has comes from the development of molecular diagnostic products. It currently sells two: the NanoChip Molecular Biology Workstation, a platform for detecting genetic mutations with forensic and biowarfare applications, and the disposable cartridges used by that platform. The products have been on the market less than two years, and the 10-year-old company remains unprofitable.
For the third quarter, it posted a net loss of $7.1 million, or 33 cents a share, a 14% improvement from the year-earlier period. Revenues jumped 12% year-over-year to $1.7 million, based on 10 sales or rentals of the workstation.
Heinzen is a fan of the company`s management. Howard Birndorf, Nanogen`s chairman and chief executive, founded six other companies, including Idec Pharmaceuticals, Ligand Pharmaceuticals (NASDAQ:LGND - News) and Gen-Probe (NASDAQ:GPRO - News). "He`s got a track record of success," says Heinzen. "He knows the bio industries and he`s the first reason we looked at it."
Others are also getting on board. The $32.6 million in cash Nanogen had at the end of the quarter represented a $4.1 million increase from the prior period, thanks to a private-equity placement that grossed $7 million in fresh capital. As part of the deal, investors received five-year warrants to purchase common stock at an exercise price of $4.75 a share, 12-month warrants at $4.75 a share and six-month warrants at $4.14 a share. If the stock stays at its current price, and investors exercise all their options, the company could receive an additional $9 million in cash.
At the end of the quarter, Nanogen forecast 2003 product revenue of less than $4 million and research revenue of $4 million. The loss for the year could approach $29 million, with cash holdings pegged at $28 million to $30 million. The company expects revenue to increase by 50% in 2004.
Quote:
"They know how to do things on a small scale and they are broadening their knowledge to get patents in other aspects in nanotechnology," says Heinzen of Emergent Financial Group. "We like the current workstation. We think it`s better, faster and will get cheaper. We think the platform will succeed. These patents are the cherry on the sundae. From the way I read it, it doesn`t deal with their day-to-day operations. But there are quite a few people out there that are looking for companies that have knowledge and patents in nanotechnology." (Heinzen owns shares of Nanogen; Emergent Financial Group doesn`t have an investment-banking relationship with the company.)
If so, you`re unusually qualified to judge the value of the ninth patent obtained this year by suitably tiny nanotech pioneer Nanogen (NASDAQ:NGEN - News).
The rest of us will just have to live with the company`s assessment that it`s "key" and the market`s verdict that proprietary insights into "an electric field assisted manufacturing platform and programmable self-assembling nanostructures" were worthy of a 51% share-price surge to a two-year high of $5.74.
Nanotechnology, a blend of chemistry and engineering, creates tiny devices or systems that operate on atomic and molecular scales. A nanometer is a billionth of a meter. By comparison, a single human cell is between 5,000 and 10,000 nanometers long.
One day, nanotech might put a supercomputer on the head of the pin. For the moment, however, it`s hard pressed to turn a profit.
Still, the microscopic discipline is enjoying lots of buzz as The Next Big Thing. On Wednesday, President Bush signed the 21st Century Nanotechnology Research and Development Act, authorizing $3.7 billion in nanotech research funding over the next four years.
Also Wednesday, Merrill Lynch held a conference call on nanotechnology. Analyst John Roy tried to convince investors that "nanotechnology could become the next growth innovation." Roy foresees uses in the fields of enhanced materials, hard-disk drives, optical networking, memory chips, medical drugs and genomic testing. And while Merrill tech strategist Steve Milunovich said during the same call that "nanotech will be over-hyped," he added that "where there`s smoke there`s fire. Nanotech is real and the intellectual-property barriers are much higher than for the Internet."
Such helpful speculation has helped Nanogen shares gain 463% since its March lows, though they still fetch less than one-sixteenth of the all-time high set in March 2000.
The latest patent, the San Diego company`s 56th overall, is the first in a series of pending applications related to the same advance. "If you think nanotechnology will be valuable in the future, this patent could be very valuable," says Tom Heinzen, vice president of Emergent Financial Group, a Minneapolis brokerage.
The company seems to agree. "The patent is important because it pertains to fundamental methods of fabricating components," says Michael Heller, a professor of bioengineering and electrical engineering at the University of California, San Diego. He co-founded Nanogen and worked on the new technology. "It`s a microchip that produces electrical fields that can control the assembly of nanocomponents. It can manipulate the nanoparticles using the electric field device," he explains
According to Heller, nanocomponents can incorporate DNA sequences giving them specific binding affinity, in effect instructions for a process of self-assembly. He says the electric fields help guide and control the self-assembly process, and allow it to be replicated on a wide scale.
"The process will help create nanostructures that can be used to create things such as features on computer chips like transistors and memory elements," says Heller. "There is a lot of evolutionary progress in the field. There are a lot of pragmatic applications, but what you haven`t seen is anything revolutionary. We haven`t seen the paradigm change yet."
Nanoparticle materials are currently being used in some not-so-sexy applications, such as grinding and polishing agents.
What little revenue Nanogen currently has comes from the development of molecular diagnostic products. It currently sells two: the NanoChip Molecular Biology Workstation, a platform for detecting genetic mutations with forensic and biowarfare applications, and the disposable cartridges used by that platform. The products have been on the market less than two years, and the 10-year-old company remains unprofitable.
For the third quarter, it posted a net loss of $7.1 million, or 33 cents a share, a 14% improvement from the year-earlier period. Revenues jumped 12% year-over-year to $1.7 million, based on 10 sales or rentals of the workstation.
Heinzen is a fan of the company`s management. Howard Birndorf, Nanogen`s chairman and chief executive, founded six other companies, including Idec Pharmaceuticals, Ligand Pharmaceuticals (NASDAQ:LGND - News) and Gen-Probe (NASDAQ:GPRO - News). "He`s got a track record of success," says Heinzen. "He knows the bio industries and he`s the first reason we looked at it."
Others are also getting on board. The $32.6 million in cash Nanogen had at the end of the quarter represented a $4.1 million increase from the prior period, thanks to a private-equity placement that grossed $7 million in fresh capital. As part of the deal, investors received five-year warrants to purchase common stock at an exercise price of $4.75 a share, 12-month warrants at $4.75 a share and six-month warrants at $4.14 a share. If the stock stays at its current price, and investors exercise all their options, the company could receive an additional $9 million in cash.
At the end of the quarter, Nanogen forecast 2003 product revenue of less than $4 million and research revenue of $4 million. The loss for the year could approach $29 million, with cash holdings pegged at $28 million to $30 million. The company expects revenue to increase by 50% in 2004.
Quote:
"They know how to do things on a small scale and they are broadening their knowledge to get patents in other aspects in nanotechnology," says Heinzen of Emergent Financial Group. "We like the current workstation. We think it`s better, faster and will get cheaper. We think the platform will succeed. These patents are the cherry on the sundae. From the way I read it, it doesn`t deal with their day-to-day operations. But there are quite a few people out there that are looking for companies that have knowledge and patents in nanotechnology." (Heinzen owns shares of Nanogen; Emergent Financial Group doesn`t have an investment-banking relationship with the company.)
Ups - wieso postet der den ganzen Artikel von oben in meinem posting?
Da sollte dies hier stehen:
Trading Spotlight
Composite Indicator
Trend Spotter (TM) Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Sell
20 Day Bollinger Bands Buy
Short Term Indicators Average: 60% - Buy
20-Day Average Volume - 1609905
Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 751020
Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 483323
Overall Average: 88% - Buy <--------
Price Support Pivot Point Resistance
5.74 4.02 5.61 7.20
Trend Spotter (TM) Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Sell
20 Day Bollinger Bands Buy
Short Term Indicators Average: 60% - Buy
20-Day Average Volume - 1609905
Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 751020
Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 483323
Overall Average: 88% - Buy <--------
Price Support Pivot Point Resistance
5.74 4.02 5.61 7.20
Long-Term Sentiment: Strong Buy 12/03/03 11:35 pm
Msg: 19981 of 20006
The float is very small. The MM`s are in a huge hole. The demand is huge.
They will continue to gap the stock higher each day until the buying pressure subsides. They have to, it is the only way they can protect themselves.
If you shorted today you are in serious trouble.
The number 1 rookie shorting mistake is shorting stocks with tiny floats because of a big move. That strategy works great with stocks that have big floats. But with 25 million shares you will get railroaded.
NGEN may hit $10 or higher tomorrow. The rookie shorts panic covering and the demand will force the MM`s to get the price to a level they can short at and will be certain to cover for a profit.
Take a look at OXGN in June of this year. They have a similar size float. Good news sent the stock from $4 to $6 on a Friday. On Monday the stock hit a high of $19.00 and spent most of the day around $16 to $17. It still has yet to go below $8.50.
So, if you think you can wait out the spike to cover, think again.
Msg: 19981 of 20006
The float is very small. The MM`s are in a huge hole. The demand is huge.
They will continue to gap the stock higher each day until the buying pressure subsides. They have to, it is the only way they can protect themselves.
If you shorted today you are in serious trouble.
The number 1 rookie shorting mistake is shorting stocks with tiny floats because of a big move. That strategy works great with stocks that have big floats. But with 25 million shares you will get railroaded.
NGEN may hit $10 or higher tomorrow. The rookie shorts panic covering and the demand will force the MM`s to get the price to a level they can short at and will be certain to cover for a profit.
Take a look at OXGN in June of this year. They have a similar size float. Good news sent the stock from $4 to $6 on a Friday. On Monday the stock hit a high of $19.00 and spent most of the day around $16 to $17. It still has yet to go below $8.50.
So, if you think you can wait out the spike to cover, think again.
www.smallcapmarketwatch.com
The hottest sector right now has to be nanotechnology and for good reason. On Tuesday the Whitehouse issued a press release announcing that President Bush will be signing the 21st Century Nanotechnology Research and Development Act on Wednesday.
The U.S. House of Representatives as well as the Senate both approved the nanotech legislation last month. The law authorizes nearly $3.7 billion over four years for research and development programs coordinated among several federal agencies. It authorizes public hearings and expert advisory panels, as well as the American Nanotechnology Preparedness Center to study the emerging technology`s potential societal and ethical effects.
The media along with all the companies in the industry will probably ramp up its pr machine this week after President Bush signs the bill. We should continue to see some great trading for the nanotech basket.
The hottest sector right now has to be nanotechnology and for good reason. On Tuesday the Whitehouse issued a press release announcing that President Bush will be signing the 21st Century Nanotechnology Research and Development Act on Wednesday.
The U.S. House of Representatives as well as the Senate both approved the nanotech legislation last month. The law authorizes nearly $3.7 billion over four years for research and development programs coordinated among several federal agencies. It authorizes public hearings and expert advisory panels, as well as the American Nanotechnology Preparedness Center to study the emerging technology`s potential societal and ethical effects.
The media along with all the companies in the industry will probably ramp up its pr machine this week after President Bush signs the bill. We should continue to see some great trading for the nanotech basket.
I think it will depend on how MMs will play it. One possible scenario:
Buyers should be aplenty so MMs wouldn`t go just shorting at $6 for a measly $1-1.5 profit.
They would go for a 1-2-3 kill:
1. MMs could continue to lend their long shares to shorts and then wait until buying demand dries out.
2. Then, when the price drops a bit they could create a major buying frenzy by going long with 2-5 million shares.
Spike will cause shorts to cover in bunches driving the price even higher.
3. When the price reaches a "target" level, MMs will sell their longs.
By causing panic both ways they will get double profits.
I believe this is how it was done with OXGN on June 9:
Open $9.78
Low: $9.31
High: $19.4
Close: $13.8
Buyers should be aplenty so MMs wouldn`t go just shorting at $6 for a measly $1-1.5 profit.
They would go for a 1-2-3 kill:
1. MMs could continue to lend their long shares to shorts and then wait until buying demand dries out.
2. Then, when the price drops a bit they could create a major buying frenzy by going long with 2-5 million shares.
Spike will cause shorts to cover in bunches driving the price even higher.
3. When the price reaches a "target" level, MMs will sell their longs.
By causing panic both ways they will get double profits.
I believe this is how it was done with OXGN on June 9:
Open $9.78
Low: $9.31
High: $19.4
Close: $13.8
Real-Time Market / ECN Get Real-Time Market / ECN for:
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.00 8:10AM ET
After Hours Change: N/A
Today`s Change: 0.26 (4.53%)
Bid: 5.99
Ask: 6.00
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.00 8:10AM ET
After Hours Change: N/A
Today`s Change: 0.26 (4.53%)
Bid: 5.99
Ask: 6.00
Real-Time Market / ECN Get Real-Time Market / ECN for:
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.10 8:13AM ET
After Hours Change: N/A
Today`s Change: 0.36 (6.27%)
Bid: 6.10
Ask: 6.10
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.10 8:13AM ET
After Hours Change: N/A
Today`s Change: 0.36 (6.27%)
Bid: 6.10
Ask: 6.10
Real-Time Market / ECN Get Real-Time Market / ECN for:
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.13 8:15AM ET
After Hours Change: N/A
Today`s Change: 0.39 (6.79%)
Bid: 6.10
Ask: 6.15
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.13 8:15AM ET
After Hours Change: N/A
Today`s Change: 0.39 (6.79%)
Bid: 6.10
Ask: 6.15
Real-Time Market / ECN Get Real-Time Market / ECN for:
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.15 8:23AM ET
After Hours Change: N/A
Today`s Change: 0.41 (7.14%)
Bid: 6.15
Ask: 6.16
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.15 8:23AM ET
After Hours Change: N/A
Today`s Change: 0.41 (7.14%)
Bid: 6.15
Ask: 6.16
Real-Time Market / ECN Get Real-Time Market / ECN for:
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.17 8:25AM ET
After Hours Change: N/A
Today`s Change: 0.43 (7.49%)
Bid: 6.17
Ask: 6.15
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.17 8:25AM ET
After Hours Change: N/A
Today`s Change: 0.43 (7.49%)
Bid: 6.17
Ask: 6.15
Real-Time Market / ECN Get Real-Time Market / ECN for:
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.20 8:30AM ET
After Hours Change: N/A
Today`s Change: 0.46 (8.01%)
Bid: 6.17
Ask: 6.20
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.20 8:30AM ET
After Hours Change: N/A
Today`s Change: 0.46 (8.01%)
Bid: 6.17
Ask: 6.20
Real-Time Market / ECN Get Real-Time Market / ECN for:
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.24 8:31AM ET
After Hours Change: N/A
Today`s Change: 0.50 (8.71%)
Bid: 6.20
Ask: 6.25
NANOGEN INC (RTM/ECN)
Symbol: NGEN
Last Trade: 6.24 8:31AM ET
After Hours Change: N/A
Today`s Change: 0.50 (8.71%)
Bid: 6.20
Ask: 6.25
seit wann bist du drin?was denkst du ist realistisch?woher hast du die außerbörslichen kurse?
Wer USA handelt, sollte doch wohl RT haben - Mann oh Mann.
Das wird ein schöner Ritt. Die Bids vorbörslich entwickeln sich genau wie Altair gestern - un da habe ich schnell 1500€ gemacht
Das wird ein schöner Ritt. Die Bids vorbörslich entwickeln sich genau wie Altair gestern - un da habe ich schnell 1500€ gemacht
schon über 500.000 stück vorbörslich gehandelt party geht weiter
Alleine 7 dicke Pakete mit je ca. 25000 Stück waren dabei
wie entwickeln sich die bids denn?
Last: 6.020 Close: 6.020 High: 0.000 Low: 0.000 Open: Change: +0.28 Volume: 531,400 Bid: 6.100 Ask: 6.100 Bid/Ask Size: 100 / 100 52 Wk High: 6.340 52 Wk Low: 1.000 %Change: 4.8% Market Cap: 143M Price/Sales: 7.8 EPS: $-1.06
Sind recht schnell angestiegen bis in den 6,20er Bereich. Aber hier eine Schätzung abzugeben, wäre sträflich. Das Ding hat eine nicht zugetraute Eigendynamik entwickelt, dass bestimmt nicht durch die 3 Milliarden vom Kongress gebremst wird, sondern wohl eine Masse Treibstoff bekommen hat.
Sollte man einsteigen oder erstmal Gewinnmitnahmen abwarten? In D geht das ASK gerade runter. 
Wenn man nicht nur auf einen Tagestrade aus ist, kann man meines Erachtens gut einsteigen - aber das muß jeder letzten Endes selber entscheiden
vorbörslich über 1.000.000 aktien gehandelt !!!
sieht doch gut aus für heute
sieht doch gut aus für heute
Aks bereits wieder bei 5 Euro - jetzt gibts wieder auf die Mütze für Nachzügler
Grad über die 6 USD rüber... Bin auch mit kleinem Geld rein und werde beim eventuellen Rücksetzer nachkaufen. Wenn´s denn einen gibt...
NANOGEN INC (NGEN) NASDAQ (National)
as of 12/04/03 11:04 ET
$6.8100 +1.0700 +18.64% Today`s Performance
Open 6.0200
Bid 6.8000
Ask 6.8300
Bid Size 87
Ask Size 1
Prev Close 5.7400
High 6.8800
Low 5.6500
52 Wk High 6.3400
52 Wk Low 1.0000
Volume 10,692,044
Restricted No
as of 12/04/03 11:04 ET
$6.8100 +1.0700 +18.64% Today`s Performance
Open 6.0200
Bid 6.8000
Ask 6.8300
Bid Size 87
Ask Size 1
Prev Close 5.7400
High 6.8800
Low 5.6500
52 Wk High 6.3400
52 Wk Low 1.0000
Volume 10,692,044
Restricted No
NANOGEN INC (NGEN) NASDAQ (National)
as of 12/04/03 11:05 ET
$6.9100 +1.1700 +20.38% Today`s Performance
Open 6.0200
Bid 6.9100
Ask 6.9300
Bid Size 11
Ask Size 50
Prev Close 5.7400
High 6.9300
Low 5.6500
52 Wk High 6.3400
52 Wk Low 1.0000
Volume 10,930,539
Restricted No
Wer sagts denn!
as of 12/04/03 11:05 ET
$6.9100 +1.1700 +20.38% Today`s Performance
Open 6.0200
Bid 6.9100
Ask 6.9300
Bid Size 11
Ask Size 50
Prev Close 5.7400
High 6.9300
Low 5.6500
52 Wk High 6.3400
52 Wk Low 1.0000
Volume 10,930,539
Restricted No
Wer sagts denn!
Die 7 Dollar haben wir bereits angekratzt - mal sehen, was da noch kommt
NanoTech Conf. Dec 8-11 Chicago
by: jab287
Long-Term Sentiment: Buy 12/04/03 11:10 am
Msg: 20129 of 20132
for more info:
http://www.nanocommerce2003.com/program.html
Das heißt bis nächste Woche liegen lassen und sich freuen!!!!!!
by: jab287
Long-Term Sentiment: Buy 12/04/03 11:10 am
Msg: 20129 of 20132
for more info:
http://www.nanocommerce2003.com/program.html
Das heißt bis nächste Woche liegen lassen und sich freuen!!!!!!
Weihnachten kommt dieses Jahr früher!!
Bin vorhin bei 4,92 EUR rein und schon wieder draußen - war ein super Trade! Ich denke, heute geht es nur noch abwärts, nach 70% Plus kein Wunder. Nächste Woche kann man wieder günstiger als heute einsteigen (hoffe ich jedenfalls).
#33
Stimmt
Und ich bin bei 2,60 vor einigen Wochen rein.
Stimmt
Und ich bin bei 2,60 vor einigen Wochen rein.
Wenn man auch nur konservativ an den Wert der 9 Patente rangeht, die die bereits besitzen, dann kommt da was ganz großes auf uns zu
Jetzt neuer Anlauf? Das Ding ist technisch völlig unberechenbar - schön
Und wir sind noch nicht einmal in der Mittagspause der Amis
Viel Glück noch !
Ich bin raus mit über 120 % Gewinn !
Danke Nanogen.
Ich bin raus mit über 120 % Gewinn !
Danke Nanogen.
Bin auch draussen!!!
Und ich danke - noch aufgestockt
...und ich bin noch drin, seit April 03
mit 1,25 !!!
Da gehts in der Zukunft noch etwas weiter gen Norden !
mit 1,25 !!!
Da gehts in der Zukunft noch etwas weiter gen Norden !
5,91 USD RT
5,97 US $ RT
6,16 US $ RT
So - heute ist wieder ein guter Tag zum Nanogen traden. Tickern bereits wieder bei 6,11 US $
6,13$
Sentiment Stockscore: 61
6,15$
6,18$
6,34$ - das wird schön
6,37$
fette Beute heute - 6,39$
6,43$ bereits - das geht wieder megafix aufwärts
6,60 - Rakete!!!
Hält sich jetzt erst mal stabil um 6,30-6,40 - mal sehen, was da noch auf uns zukommt.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +2,26 | |
| -0,50 | |
| +1,62 | |
| -3,39 | |
| +0,66 | |
| -0,37 | |
| -16,67 | |
| -1,52 | |
| 0,00 | |
| +0,33 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 224 | ||
| 164 | ||
| 93 | ||
| 90 | ||
| 63 | ||
| 55 | ||
| 52 | ||
| 39 | ||
| 38 | ||
| 37 |
